Market cap
$84 Mln
Recently Viewed
Clear AllMarket cap
$84 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-27 Mln
ROE
-0.8 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.1
Debt to Equity
0.8
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
2,759,220
CFO
$-340.03 Mln
EBITDA
$-409.96 Mln
Net Profit
$-396.43 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neovasc - ADR
| 90.1 | 2.4 | 7.6 | 217.9 | -22.3 | -52.7 | -53.0 |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Neovasc - ADR
| -50.6 | -82.4 | -10.3 | -99.0 | -65.3 | -61.6 | -34.0 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include Tiara for the transcatheter treatment of mitral valve disease; and the... Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada. As of April 11, 2023, Neovasc Inc. operates as a subsidiary of Shockwave Medical, Inc. Read more
Pres, CEO & Director
Mr. Fredericus A. Colen
Pres, CEO & Director
Mr. Fredericus A. Colen
Headquarters
Richmond, BC
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Neovasc Inc - ADR is $30.03 (NASDAQ) as of 19-Apr-2023 09:30 EDT. Neovasc Inc - ADR has given a return of -22.29% in the last 3 years.
Since, TTM earnings of Neovasc Inc - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
-0.06
|
0.03
|
|
2020
|
-0.03
|
0.48
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of Neovasc Inc - ADR are Rs -- and Rs -- as of 25-Apr-2026.
Neovasc Inc - ADR has a market capitalisation of $ 84 Mln as on 20-Apr-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Neovasc Inc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.